8-K: HeartSciences Reports Q3 Fiscal 2025 Results and Business Update, Eyes FDA Submissions

HeartSciences reports progress towards FDA submissions and advancements in AI-ECG technology for Q3 Fiscal Year 2025.

Summary

• HeartSciences reported its Q3 fiscal 2025 results, highlighting progress towards FDA submissions for its products.
• The company is focused on modernizing the ECG industry with AI-powered technology.
• HeartSciences expects to finalize the FDA study clinical validation for the MyoVista wavECG device soon and anticipates submitting it for FDA clearance in the first half of calendar 2025.
• The company is in active discussions for MyoVista Insights to be implemented in test sites during 2025, following the completion of Phase 1 in December 2024.
• HeartSciences aims for Phase 2 regulatory submission for MyoVista Insights in the second half of calendar 2025, along with the first cloud-based algorithm.
• The company successfully undertook pre-validation work with Rutgers Robert Wood Johnson Hospital System on the low ejection fraction (LVEF 40) algorithm licensed from Icahn School of Medicine at Mount Sinai, New York in February 2025.
• HeartSciences' AI-ECG algorithm was included in the CMS 2025 OPPS final rule, enabling reimbursement upon commercial launch.
• There were no revenues during Q3 FY2025.
• As of January 31, 2025, cash and cash equivalents were approximately $2.6 million and shareholders equity was approximately $1.8 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress towards FDA submissions and the potential of the AI-ECG technology, but tempered by the lack of revenue and limited cash reserves.

Positives

• The company is making significant progress towards FDA submissions for its MyoVista wavECG device.
• MyoVista Insights has completed Phase 1 and is in discussions for test site implementation.
• The 'app store' approach for AI-ECG algorithms could reduce development costs and regulatory burden.
• Inclusion in the CMS 2025 OPPS final rule enables reimbursement for AI-ECG upon commercial launch.
• The company has a collaboration with Icahn School of Medicine at Mount Sinai.

Negatives

• The company reported no revenues for Q3 FY2025.
• The company had cash and cash equivalents of approximately $2.6 million as of January 31, 2025.
• The company had shareholders equity of approximately $1.8 million as of January 31, 2025.

Risks

• The company's success is dependent on receiving FDA clearance for its products.
• The company's future financial performance is subject to various risks and uncertainties, including market conditions and competition.
• The company's cash position may require additional funding in the future.

Future Outlook

HeartSciences anticipates submitting the MyoVista wavECG device for FDA clearance within the first half of calendar 2025 and aims for Phase 2 regulatory submission for MyoVista Insights in the second half of calendar 2025. The company also intends for MyoVista Insights to serve as an ECG management system in Phase 3.

Management Comments

• Following the meeting with the FDA in February, clinical validation for the MyoVista wavECG device is expected within weeks and, assuming it is successful, FDA submission would follow soon after in the first half of the year.
• Feedback on MyoVista Insights cloud-native platform has been excellent, and we are in active discussion for early deployment in test environments.
• Our ultimate vision is to offer a path to modernize legacy ECG management systems, as they are generally inflexible and costly due to decades-old IT architecture.
• CMS has already established reimbursement for AI-ECG at a rate significantly higher than that of conventional ECG.

Industry Context

HeartSciences is positioning itself to modernize the ECG industry by leveraging AI and cloud-based technology. The company aims to address the limitations of traditional ECG devices and management systems, offering improved diagnostic capabilities and cost-effectiveness.

Comparison to Industry Standards

• HeartSciences is differentiating itself by building next-gen ECG device hardware, device agnostic cloud-native software and AI-ECG algorithms, unlike many competitors who focus on only one aspect.
• The company's 'app store' approach for AI-ECG algorithms is intended to reduce costs and regulatory burden compared to developing all algorithms in-house, a strategy that could be more efficient than competitors relying solely on internal development.
• The company's cloud-native MyoVista Insights platform aims to provide a lower-cost and more interoperable solution compared to traditional on-premise ECG management systems, potentially offering a competitive advantage over established vendors in the ECG management market.

Stakeholder Impact

• Shareholders may benefit from the potential commercialization of HeartSciences' products and the modernization of the ECG industry.
• Clinicians may benefit from improved diagnostic capabilities and cost-effective solutions for cardiac screening.
• Patients may benefit from earlier and more accurate detection of heart disease.

Next Steps

• Finalize the FDA study clinical validation for the MyoVista wavECG device.
• Submit the MyoVista wavECG device for FDA clearance in the first half of calendar 2025.
• Implement MyoVista Insights in test sites during 2025.
• Aim for Phase 2 regulatory submission for MyoVista Insights in the second half of calendar 2025.
• Perform FDA validation studies using retrospective data for the low ejection fraction algorithm.

Key Dates